According to UnivDatos, the PARP inhibitors market was valued at USD 4723.5 Million and is expected to grow at a strong CAGR of around 12.9% during the forecast period (2024-2032) owing to investment in PARP inhibitors. The introduction of poly (ADP-ribose) polymerase (PARP) inhibitors has significantly reshaped the cancer treatment landscape in the United States. These targeted therapies have...